The virtual meeting a few weeks ago was a success, thanks to the presenters and the audience!
Most of the presentations have now been uploaded to the website, and you can find them under the tab ‘Past Meeetings’ above. There you will also find presentations from some of the previous TriNation meetings.
Following the deadline for the submission of abstracts to the 2021 meeting, we have now made a tentative program for the meeting. All presenters will be contacted within the next few days and asked to confirm their presentation.
The meeting will take place as a virtual meeting from 12.30-16.00 CET on April 21st and 22nd. Registration to the meeting will open mid february, and more information on this will be provided at that time.
The tentative program overview:
Wednesday April 21st 12.30-16.00
12.30-13.40: Session I: Welcome and situation updates
14.15-15.00: Session II: Experience from the field
15.15-16.00: Session III: CMS –host interaction and diagnostic potential
Thursday April 22nd 12.30-16.00
12.30-13.30: Session IV: Molecular epidemiology
13:45-14:10: Intermission:Information from TriNation and our sponsors
14.10-15.15: Session V: Vaccine development
15.15-16.00: Session VI: Vaccine evaluation
Due to the Covid-19 pandemic, the 2020 TriNation meeting will not be held in November 2020 as originally planned.
Instead, the meeting will be planned to take place on April 21-22nd 2021. We are planning to host a physical meeting, and have reserved the Scottish Government building at Victoria Quay in Edinburgh.
Information on abstract submission and the program will follow in due course.
The 2020 meeting will take place at Victoria Quay in Edinburgh, which provides an easily accessible venue for participants from all countries. The meeting will be from November 10th-12th 2020.
The program is under planning, and will include the following sessions:
-Welcome & Situation updates from (PD, CMS & HSMI)
-Experience from the production and the use of management strategies to mitigate disease.
-Vaccination and control. Special focus on experience from field use of CLYNAV and on best practice for administering vaccine.
-Experience with the use of functional feed in the field.
-Welfare and viral cardiomyopathies. Factors that influences mortality, ie. Mechanical lice treatments and concurrent infections with gill pathogens.
In addition, we invite scientists or industry representatives to submit presentations on current research updates on PD, CMS or HSMI.